» Articles » PMID: 22788259

The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt: a Government Perspective Analysis

Overview
Specialty Pharmacology
Date 2012 Jul 14
PMID 22788259
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We evaluated national rotavirus (RV) immunization programme costs to estimate how resulting changes in morbidity and mortality will influence government fiscal accounts over time. The assumption was that increased childhood survival in vaccinated cohorts leads to increased numbers of children consuming government resource, and an increased number of future tax payers.

Objective: Our objective was to evaluate the difference in lifetime discounted net tax revenue generated by RV vaccinated and unvaccinated cohorts from the Egyptian government perspective.

Methods: The model framework adopts the Egyptian government perspective for RV immunization costs (year 2009 values) and all government transfers (e.g. education costs, health costs, pensions). To reflect the government tax revenue, we applied a fixed income tax burden to earnings over the lifetime of vaccinated and unvaccinated cohorts. At each year of the model, we derive net taxes (gross taxes less transfers) discounted to the immunization year to reflect the present value of RV vaccination investment costs.

Results: Projected incremental net present values of the vaccinated cohort versus the unvaccinated cohort are $US6.1 million, $US58.1 million and $US55.7 million at 25-, 50- and 72-year time horizons, respectively. The internal rate of return for the government based on RV vaccination at years 25, 50 and 72 was 10.8%, 15.1% and 14.9, respectively. Within the first 5 years of vaccination, 76% of vaccine acquisition costs were offset due to direct and indirect cost savings attributed to a reduction in RV-related disease burden. Investments in RV vaccination in a single year are entirely offset when the vaccinated cohort of newborns reach 22 years of age.

Conclusion: The government perspective is useful for evaluating investments in RV vaccination because of ongoing government transfers and tax receipts attributed to changes in RV-attributed morbidity and mortality. The analysis described here illustrates that investing in RV offers tangible long-term fiscal benefits for government over many generations that would not ordinarily be captured in economic evaluations typically applied to healthcare interventions.

Citing Articles

Can mathematicians help to solve social-justice problems?.

Crowell R Nature. 2024; .

PMID: 38778191 DOI: 10.1038/d41586-024-01494-7.


The Impact of Rapid Handpump Repairs on Diarrhea Morbidity in Children: Cross-Sectional Study in Kwale County, Kenya.

Thomson P, Stoler J, Byford M, Bradley D JMIR Public Health Surveill. 2024; 10():e42462.

PMID: 38227359 PMC: 10828938. DOI: 10.2196/42462.


Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling-The Tool of Choice for Assessing Public Finance Sustainability.

van der Schans S, Schottler M, van der Schans J, Connolly M, Postma M, Boersma C Vaccines (Basel). 2023; 11(4).

PMID: 37112735 PMC: 10142088. DOI: 10.3390/vaccines11040823.


Estimating the Fiscal Consequences of National Immunization Programs Using a "Government Perspective" Public Economic Framework.

Connolly M, Kotsopoulos N Vaccines (Basel). 2020; 8(3).

PMID: 32887265 PMC: 7564721. DOI: 10.3390/vaccines8030495.


How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.

Standaert B, Sauboin C, DeAntonio R, Marijam A, Gomez J, Varghese L J Mark Access Health Policy. 2020; 8(1):1719588.

PMID: 32128075 PMC: 7034472. DOI: 10.1080/20016689.2020.1719588.


References
1.
Rice D, Cooper B . The economic value of human life. Am J Public Health Nations Health. 1967; 57(11):1954-66. PMC: 1227852. DOI: 10.2105/ajph.57.11.1954. View

2.
Linhares A, Velazquez F, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F . Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008; 371(9619):1181-9. DOI: 10.1016/S0140-6736(08)60524-3. View

3.
Kurugol Z, Geylani S, Karaca Y, Umay F, Erensoy S, Vardar F . Rotavirus gastroenteritis among children under five years of age in Izmir, Turkey. Turk J Pediatr. 2004; 45(4):290-4. View

4.
Schael I, Gonzalez R, Salinas B . Severity and age of rotavirus diarrhea, but not socioeconomic conditions, are associated with rotavirus seasonality in Venezuela. J Med Virol. 2009; 81(3):562-7. DOI: 10.1002/jmv.21420. View

5.
Gianino P, Mastretta E, Longo P, Laccisaglia A, Sartore M, Russo R . Incidence of nosocomial rotavirus infections, symptomatic and asymptomatic, in breast-fed and non-breast-fed infants. J Hosp Infect. 2002; 50(1):13-7. DOI: 10.1053/jhin.2001.1129. View